Search results for "From ACP Journal Club"


 
Results 61 - 70 of about 129 for "From ACP Journal Club".

Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations | ACP Diabetes Monthly

Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.

August 12, 2016 | ACP Diabetes Monthly

ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.

November 13, 2015 | ACP Diabetes Monthly

ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.

February 8, 2013 | ACP Diabetes Monthly

ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.

November 11, 2016 | ACP Diabetes Monthly

ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.

Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo | ACP Diabetes Monthly

A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.

Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia | ACP Diabetes Monthly

Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.

Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more | ACP Diabetes Monthly

Hypertension treatment reduced mortality and myocardial infarction in diabetic patients with a systolic blood pressure of at least 140 mm Hg, a systematic review and meta-analysis found. However, in patients with lower baseline blood pressure (BP),

Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk | ACP Diabetes Monthly

Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.

November 8, 2013 | ACP Diabetes Monthly

ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next